HEC-68498 is under clinical development by HEC Pharma and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HEC-68498’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HEC-68498 is under development for the treatment of idiopathic pulmonary fibrosis and solid tumors including colorectal cancer, breast cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), triple negative breast cancer and neuroendocrine cancers. The drug candidate is administered through oral route. It acts by targeting phosphatidylinositol 3 Kinase (PI3K) and mechanistic target of rapamycin (mTOR).
HEC Pharma overview
HEC Pharma is a private company, The Company mainly develops, produces, and distributes active pharmaceutical ingredients, insulins, and more. It is headquartered in Dongguan, Guangdong, China.
For a complete picture of HEC-68498’s drug-specific PTSR and LoA scores, buy the report here.